Weight-Loss Injections May Cut Deadly Heart Attack Complications, New UK Research Suggests

Weight loss injections currently used by thousands of patients across the UK could hold the key to preventing life-threatening complications from a heart attack, according to a new study carried out by British experts.

Researchers at several NHS Trusts carried out a study that showed patients who were given a commonly prescribed weight loss injection shortly after a heart attack were at a lower risk of heart failure during the recovery stage.

This raises the possibility of drugs first developed for obesity and type 2 diabetes having a broader application in the treatment of heart patients.

A new use for familiar drugs

The drugs studied in the research are called GLP-1 receptor agonists. They are designed to stimulate the action of a hormone that regulates blood sugar and appetite. In the last few years, the drugs have become well known for aiding people in the loss of significant amounts of weight.

Doctors, however, have noted that patients who use the drugs experience improvements to blood pressure, cholesterol, and overall heart health. This has prompted research to see if the drugs can actually benefit the heart when it has been damaged.

When someone suffers a heart attack, the flow of blood to the heart muscle is blocked. Even though the patient might survive the experience, the damage to the muscle can cause the heart to become weakened. This can cause the patient to suffer from a number of different issues, such as heart failure. Heart failure occurs when the heart is not able to pump blood throughout the body.

What the study found

The UK study involved over 1,500 patients who had recently experienced a heart attack. The patients were randomly selected to receive either the usual care after a heart attack or the usual care after a heart attack combined with a weekly weight loss injection.

After one year, researchers noticed that patients who received the injection had fewer hospital admissions related to heart failure. In addition, early results showed that patients who received the injection experienced better heart function on scans six months after treatment started.

The researchers think that the injections may help patients because they may help fight heart failure by reducing inflammation and improving the use of energy in heart muscle cells. Inflammation is known to play a major role in heart muscle cell death after a heart attack.

Dr. Helen Carter, a cardiologist who participated in the study, said that the results of the study were good news, but more monitoring is needed.

"We are not suggesting that these injections replace current treatments, but they may provide an additional level of protection during a critical time in a patient's recovery."

Why this matters in the UK

Approximately 100,000 people are currently hospitalized annually in the UK due to a heart attack. Though the chances of survival have increased due to emergency treatment, the risk of complications after a heart attack is still high.

Heart failure is a condition that affects over a million people in the country, and this is a major problem for the NHS. Medications that reduce the risk of heart failure after a heart attack will reduce the burden on hospitals and also improve the lives of patients.

According to Professor Martin Shaw, a heart expert who was not a part of the study, “The research adds to the wealth of evidence that GLP-1 drugs have a positive effect on the heart. We’ve known for some time that these medications can reduce the risk of heart attacks in high-risk patients. What’s particularly interesting here is the suggestion that they may also limit the damage once a heart attack has already happened.”

Cost and access questions remain

Despite the promising findings, there are doubts about the cost and accessibility of these drugs. Weight loss injections, such as semaglutide, are currently available to NHS patients under strict conditions, often for the treatment of obesity or diabetes.

The treatment of heart attack patients with these drugs, however, will need more trials and a review by drug regulators. Side effects, such as nausea and gastrointestinal discomfort, are also a factor to be considered in such seriously ill patients.

According to health economists, the cost of these drugs might be justified if fewer people develop chronic heart failure, which is a costly condition to manage.

What happens next?

The research team also intends to continue tracking the subjects for a few more years to find out if the reduction in heart failures results in fewer deaths.

Currently, patients are advised not to seek weight loss injections for the prevention of heart attacks unless they are used to treat another approved medical condition.

The research also indicates that drugs meant to treat one health condition may have the unexpected effect of helping to treat another.

If the research is validated, weight loss injections could become part of the treatment process for heart attack victims in the UK not for weight loss, but to help the heart recover from the attack and reduce the chances of fatal consequences.